Tag Archive for: Tregs

Combinations of iOnctura’s roginolisib revert immune suppression in immunotherapy-resistant NSCLC

Late breaking data from ongoing Phase I/II PULMO-01, the first clinical study of conformation-selective PI3Kδ inhibitor roginolisib in immunotherapy-resistant non-small cell lung cancer (NSCLC), presented at SITC Data demonstrated roginolisib-containing regimens were tolerable, reduced immunosuppressive activated regulatory T cells (Tregs) and expanded stem-like CD8+ T cells The ‘chemo-free’ (roginolisib plus dostarlimab) arm exhibited the most […]

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe

First patient dosed in France, expanding the DOMISOL study beyond Australia DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program Montreal, Canada – Strasbourg, France – Boston, United States, April 9, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

© Optimum Strategic Communications.